![Schematic view of the PPARα structure.\
Domain structure of the PPARα protein (A) with the ligand-independent activation function 1 (AF1) domain or A/B domain shown in blue, the DNA-binding domain (DBD) or C domain shown in yellow, the hinge or D domain shown in orange, and the ligand-binding domain (LBD) or E domain together with the activation function 2 (AF2) or F domain shown in green. (B) Schematic representation of the PPARα protein with phosphorylation sites labeled with yellow stars, the corepressor site labeled with a red circle, and the coactivator binding site shown with a blue hexagon.](nrs08002.f1){#fig1}

![Biological ligands of PPARα.\
Diagram illustrating different known biological ligands of PPARα. Metabolic sources for ligands are grouped in the boxes together with ligand generating enzymes marked with an asterisk, ligands marked with a square and ligand degrading enzymes marked with a triangle. The PPARα and RXRα heterodimer are shown bound to a PPRE sequence in the promoter of a target gene with associated coactivator proteins forming a complex with the cellular transcription machinery.](nrs08002.f2){#fig2}

![Levels of regulation of PPARα-mediated transcription.\
Diagram illustrating the different factors which regulate the ability of PPARα to activate or repress transcription of target genes. Five major levels of regulation are: (1) the ligand, (2) the receptor expression, (3) the promoter, (4) the coactivator proteins and (5) the expression of target genes.](nrs08002.f3){#fig3}

###### Some known PPARα coactivator proteins.

Coactivator proteins known to interact with activated PPARα, with their enzymatic activities and functions. Acronyms used: (MT) Methyltransferase, (HAT) Histone acetyltransferase. References identifying each protein as a coregulator of PPARα are provided in the reference section.
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Introduction
============

Peroxisome proliferator-activated receptor (PPAR) α (NR1C1), β/δ (NR1C2), and γ (NR1C3), are ligand-activated transcription factors that are members of the nuclear-hormone receptor (NR) superfamily \[[@r9]; [@r81]; [@r234]\]. The foundation for the discovery and designation of the PPAR subfamily of nuclear receptors in the 1990s \[[@r47]; [@r81]\], is the cumulative work over the preceding 25 years with peroxisome proliferators (PPs), a group of structurally diverse chemicals that lower serum lipids, and induce massive proliferation of peroxisomes in liver cells, with associated coordinated transcriptional activation of peroxisomal fatty acid β-oxidation system genes \[[@r169]; [@r161]; [@r162]; [@r165]\]. A receptor for these chemicals was originally postulated in the mid 1980s \[[@r105]; [@r106]; [@r156]; [@r168]\] to account for the cell-specific highly reproducible pleiotropic responses \[[@r170]\]. Chronic exposure to PPs results in the development of liver cancer in rats and mice, although these agents are nonmutagenic \[[@r156]; [@r169]; [@r162]\]. It was therefore envisaged that a receptor-mediated mechanism is responsible for both the immediate and long-term effects of PPs, including the development of liver cancer \[[@r156]; [@r170]\]. A search for a receptor for these ligands was underway \[[@r105]\], and this culminated in the cloning of a receptor activated by PPs by Issemann and Green \[[@r81]\]. This receptor was appropriately designated PP-**A**ctivated **R**eceptor or PPAR \[[@r81]\]. Subsequent identification of two other members of this family, namely PPARβ/δ and PPARγ, resulted in designating the original receptor activated by PPs as PPARα \[[@r47]\]. Gene knockout studies in mice have unequivocally established that PPARα is indeed responsible for the PP-induced array of pleiotropic responses including liver cancer in rodents \[[@r108]\].

All three members of the PPAR subfamily function as sensors for fatty acids and fatty acid derivatives, and thus control important metabolic pathways involved in lipid and energy metabolism \[[@r22]; [@r102]\]. In the liver, PPARα is activated by synthetic PPs and by both saturated and polyunsaturated fatty acids and their derivatives, and regulates fatty acid oxidation systems to increase energy combustion. PPARα also plays a role in lipoprotein synthesis, inflammatory responses and the development of cancer in the rodent liver \[[@r108]; [@r125]; [@r129]\]. PPARβ/δ also enhances fatty acid catabolism and energy uncoupling in skeletal muscle and adipose tissue as well as recently shown in the liver where it may participate in the hepatic response to starvation \[[@r180]; [@r211]\]. Additionally, PPARβ/δ may play a protective role in the liver by downregulating inflammatory signals in circumstances of liver damage \[[@r131]; [@r189]; [@r190]\]. Together, PPARα and PPARβ/δ are active participants in energy burning, whereas PPARγ, which has two isoforms, PPARγ1 and PPARγ2, is critical in regulating adipocyte differentiation and energy storage by adipocytes \[[@r99]; [@r202]; [@r229]\]. PPARγ can also induce lipid accumulation in other cell types, such as hepatocytes, when overexpressed \[[@r219]\]. In essence, PPARγ regulates anabolic lipid metabolism, while PPARα and PPARβ/δ function as catabolic regulators of energy \[[@r23]; [@r202]; [@r211]\].

The PPARα gene and protein structure
====================================

The human PPARα (NR1C1) gene, which spans \~93.2 kb, is located on chromosome 22 at position 22q12-q13.1 and it encodes a protein of 468 amino acids \[[@r193]\]. The mouse PPARα gene, located on chromosome 15E2, also encodes a protein of 468 amino acids \[[@r81]\]. As in the mouse, the human PPARα gene encoded mRNA is derived from 8 exons with a 5\' untranslated region encoded by exons 1, 2, and part of exon 3 \[[@r41]; [@r193]\]. The remainder of exon 3 and exons 4-8 contribute to the coding region of PPARα \[[@r41]; [@r193]\]. The last 232 bp of exon 8 contribute to the 3\'-untranslated region \[[@r208]\].

PPARα shares common structural characteristics with the other members of the NR family \[[@r41]\]. It displays five distinguishable domains designated the A/B, C, D, E and F domains, respectively ([Figure 1](#fig1){ref-type="fig"}). The PPARα N-terminal A/B domain contains an activation function-1 (AF-1) region. This region has a low level of basal transcriptional activity and functions independent of ligand-binding \[[@r41]\]. The specificity of gene transcription is granted by the isoform-specific sequence of the A/B domain of the receptor \[[@r77]\]. Chimeric proteins generated by fusion with the A/B domains of other receptor proteins attenuate the specificity of target gene activation \[[@r77]\]. The A/B domain is followed by a DNA-binding domain (C) encompassing amino acids 101-166 in the human that contains two very highly conserved zinc finger motifs and architectural elements capable of sequence-specific binding to DNA \[[@r41]\].

Next to the DNA-binding domain is a flexible hinge domain (D), which connects the DNA-binding domain and the ligand-binding domain (E) \[[@r41]\]. This hinge region binds corepressor proteins, with the characteristic LXXXIXXXL repressor motif, to the receptor in its quiescent, unliganded state \[[@r46]\]. The corepressor-binding site partly overlaps with the coactivator-binding site. The ligand binding domain in the human PPARα protein extends from amino acids 280-468 and contains an activation function-2 (AF-2) region composed of two α-helices flanking one four-stranded β-sheet \[[@r41]\]. The AF-2 domain is repressed until ligand-binding occurs. Following ligand-binding, the AF-2 domain undergoes a conformational shift, which allows the formation of hydrogen bonds between Tyr-314 and Tyr-464, as well as the formation of a charge clamp between Glu-462 and Lys-292 \[[@r215]\]. This conformational change in the protein allows interaction of the receptor with the LXXLL (L, leucine; X, any amino acid) motifs located in coactivator proteins \[[@r215]\]. PPARα, like other nuclear receptors, will undergo conformational adjustment upon binding to a ligand to achieve the coregulator exchanges and activation of the target genes \[[@r215]\].

The PPAR ligand binding cavity, with a total volume of 1300 to 1400 A°, is larger than that found in other NRs \[[@r41]; [@r215]\]. It is defined by 34 amino acid residues and 80% of these residues are highly conserved across the three PPAR subtypes \[[@r47]\]. PPARα and PPARγ ligand binding cavities are similar in size, but the PPARβ/δ pocket is significantly narrower in the region adjacent to the AF-2 helix and does not readily accommodate bulky polar heads \[[@r40]\]. Similarity between PPARα and PPARγ ligand binding pockets may account for some degree of flexibility in ligand-receptor interaction between these two isoforms and their ability to bind a wide range of synthetic and natural lipophilic compounds \[[@r215]\]. Comparison of the crystal structures of the ligand binding domains showed that a single amino acid, tyrosine 314 in PPARα and histidine 323 in PPARγ, accounts for the subtype selectivity for classes of ligands \[[@r215]\]. The PPARα pocket is more lipophilic than that of PPARγ and this may account for the greater affinity of PPARα to bind the more lipophilic-saturated fatty acids \[[@r215]\].

Expression of PPARα
===================

PPARα belongs to the type II nuclear receptor family and like the other two PPAR isotypes, is localized in the nucleus. This differs from type I nuclear receptors, which are cytosolic and translocate to the nucleus upon ligand-binding. High levels of PPARα expression are found in tissues with active fatty acid catabolism, such as liver, heart, kidney, brown adipose tissue, muscle, small intestine and the large intestine \[[@r9]; [@r11]; [@r81]\]. Similar tissue expression profiles of PPARα have been found in rodents and human \[[@r9]\]. PPARα exerts a dominant role in fatty acid catabolism and ketone body synthesis in the liver \[[@r96]\]. PPARβ/δ also participates in energy catabolism, but its effects are more prominent in muscle and heart, though it also regulates some genes in the liver \[[@r180]\]. In contrast, PPARγ is expressed abundantly in white adipose tissue, where it is involved in lipid storage and in brown adipose tissue, where it participates in energy dissipation \[[@r202]\].

While PPARα regulates many target genes, the expression of the PPARα gene itself is under the control of other transcription factors \[[@r148]\]. In rodents, PPARα is regulated by various physiological conditions such as stress, hormones (including growth hormone), glucocorticoids, insulin, and leptin \[[@r79]; [@r109]\]. PPARα expression is also reported to be related to aging \[[@r150]\], and is induced during brown adipocyte differentiation \[[@r95]\]. Expression levels of PPARα in mouse liver are increased during starvation and this leads to enhanced expression of PPARα target genes in liver to catabolize influxed fatty acids \[[@r96]\]. Human PPARα is also regulated at the transcriptional level by nuclear receptors, such as hepatocyte nuclear factor 4 (HNF4), and chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) \[[@r148]\]. HNF4 positively regulates PPARα expression via a direct repeat 1 (DR1) element, which is composed of the consensus sequence AGG(A/T)CA separated with a single nucleotide spacing between two repeats \[[@r148]\]. On the other hand, the DR1 element in the human PPARα promoter is antagonized by the orphan receptor COUP-TFII \[[@r148]\]. Furthermore, PPARα appears to modulate its own expression \[[@r35]\]. In human liver, PPARα mRNA levels may vary significantly among individuals and are considered lower than the levels noted in rodent livers, but this may in part be related to variations in liver sample procurement for the frozen archival liver bank \[[@r141]; [@r209]\]. PPARα transcript levels are also induced during macrophage differentiation by high glucose levels \[[@r177]\]. PPARα is also regulated by the ubiquitin proteasomal degradation system \[[@r60]\].

Posttranslational modifications
===============================

A truncated PPARα isoform resulting from a posttranslational exon skipping mechanism has been detected in human, swine, and jerboas \[[@r49]; [@r61]\]. This truncated form harbors dominant negative transcriptional repressive activity on PPARα. In addition, PPARα activity is regulated by posttranslational modifications such as phosphorylation ([Figure 1](#fig1){ref-type="fig"}). PPARα was first shown to be phosphorylated in primary rat adipocytes in culture \[[@r192]\]. Insulin treatment increases PPARα phosphorylation and nearly doubles its transcriptional activity in CV-1 and HepG2 cells in culture \[[@r192]\]. This insulin-mediated phosphorylation of PPARα involves amino acids Ser12 and Ser21 \[[@r93]\]. Stress stimuli exert an increase in PPARα phosphorylation in rat neonatal cardiac myocytes by the p38 mitogen-activated protein kinase (MAPK) pathway \[[@r6]\]. p38 MAPK phosphorylates Ser 6, 12 and 21 residues located within the N-terminal A/B domain of the protein and this phosphorylation significantly enhanced ligand-dependent transactivation of PPARα \[[@r6]\]. PPARα is also reported to be phosphorylated by protein kinase C (PKC). Inhibition of PKC activity impairs ligand-activated PPARα transactivation activity, but enhances PPARα transrepression activity. Purified PPARα protein is phosphorylated *in vitro* by recombinant PKCα and -βII. These data demonstrate that the PKC signaling pathway may act as a molecular switch for the transactivation and transrepression properties of PPARα, which involve phosphorylation of Ser179 and Ser230 \[[@r8]\]. This PKC phosphorylation of PPARα is believed to play an important role in statin-mediated acute anti-inflammatory effects, though the importance of phosphorylation in PPARα signaling has never been clearly demonstrated *in vivo* \[[@r145]\].

PPARα ligands
=============

PPARα ligands fall into two general categories: *synthetic xenobiotics* (exogenous) and *biological molecules* (endogenous). Synthetic ligands, referred to as PPs, include hypolipidemic drugs such as clofibrate, fenofibrate, gemfibrozil, bezafibrate, ciprofibrate, nafenopin, methyl clofenapate, tibric acid, and Wy-14,643 (pirinixic acid) used in the treatment of dyslipidemias, and industrial phthalate-monoester plasticizers, such as di-(2-ethylhexyl)-phthalate (DEHP), and di-(2-ethylhexyl) adipate (DEHA) used in the manufacture of polyvinyl chloride plastics \[[@r106]; [@r116]\]. Certain herbicides, pesticides, industrial solvents, food flavoring agents, and leukotriene D4 receptor antagonists also function as PPARα ligands \[[@r116]\]. These structurally-diverse chemicals induce highly reproducible and similar pleiotropic responses in the rat and mouse liver. Proliferation of peroxisomes in liver parenchymal cells and profound transcriptional activation of fatty acid oxidation system genes are the hallmarks of PP-induced pleiotropic responses in the rat and mouse liver.

Endogenous or naturally-occurring biological molecules that serve as PPARα ligands include fatty acids and fatty acid derivatives ([Figure 2](#fig2){ref-type="fig"}) \[[@r42]; [@r75]\]. Endogenous PPARα activators, in most part, have been identified using *in vitro* approaches \[[@r59]; [@r65]; [@r75]; [@r102]\]. Both dietary saturated and unsaturated fatty acids function as direct ligands for PPARα \[[@r75]\]. Alternately, the ultimate ligands for this receptor may be generated during fatty acid catabolism and new fatty acid synthesis *in vivo* \[[@r17]\] ([Figure 2](#fig2){ref-type="fig"}). Several enzymes such as the 8-, 12-, 15- and 5-lipoxygeneases, the cyclooxygenases and cytochrome P450s utilize fatty acids as substrates to produce putative PPARα ligands \[[@r12]; [@r38]; [@r135]\]. Although many synthetic ligands activate PPARα efficiently, it appears that PPARα has evolved primarily for lipid sensing to regulate energy combustion \[[@r160]; [@r175]\].

Evidence suggests that PPARα senses certain endogenous lipid metabolic intermediates as ligands and participates in their metabolism (degradation) by inducing downstream lipid metabolism-related genes \[[@r54]\]. The first *in vivo* evidence came from studies with fatty acyl-CoA oxidase 1 (ACOX1) gene disrupted mice, in that mice deficient in this first and rate-limiting enzyme of the fatty acid β-oxidation system reveal profound activation of PPARα in liver \[[@r53]; [@r54]; [@r217]\]. Animals deficient for the ACOX1 have high levels of the very long chain fatty acids and since very-long chain fatty acyl-CoAs are incapable of entering the fatty acid oxidation pathway due to ACOX1 deficiency, these unmetabolized substrates act as ligands to hyperactivate PPARα \[[@r54]; [@r217]\]. Recent studies with other gene knockout mouse models suggest that enzymes such as ACOX1, enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase (L-PBE/MFP), D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase (D-PBE/MFP2) and sterol carrier protein x (SCPx) are necessary for the degradative metabolism of endogenously-generated PPARα ligands \[[@r50]; [@r54]; [@r87]; [@r119]; [@r153]; [@r187]\], while other enzymes such as fatty-acid synthase (FAS), fatty acyl-CoA synthetase (FACS) and certain lipoxygenases (LO), are required for PPARα ligand generation \[[@r17]; [@r120]; [@r220]\]. It is implied that substrates of ACOX1, such as very long-chain fatty acyl-CoAs, when left unmetabolized in the absence of this enzyme, function as potent endogenous ligands of PPARα \[[@r54]; [@r217]\]. It is known that long-chain acyl-CoA esters can act as regulatory molecules *in vivo* \[[@r52]; [@r53]; [@r54]; [@r75]\]. PPARα exhibits high affinity for the CoA thioesters of the common (C20-C24) very long chain fatty acids and these CoA thioesters of very-long chain and branched-chain fatty acids are more potent PPARα ligands than the free fatty acids \[[@r75]\]. Further evidence that fatty acids are not the direct *in vivo* ligands for PPARα comes from mice with disrupted fatty acyl-CoA synthetase gene \[[@r113]\]. Fatty acyl-CoA synthetases activate long-chain fatty acids to acyl-CoAs, thereby providing substrates for downstream fatty acid β-oxidation pathways \[[@r113]\]. Mice with a disrupted fatty acyl-CoA synthetase 1 gene \[[@r113]\], or deficient for the adrenoleukodystrophy protein gene (X-ALD) \[[@r72]; [@r174]\], fail to convert fatty acids to acyl-CoAs to serve as substrates for fatty acid β-oxidation vis à vis ligands for PPARα \[[@r72]; [@r113]\]. If long-chain fatty acids function as PPARα ligands *in vivo*, one would have expected increased PPARα target gene activation in X-ALD and fatty acyl-CoA synthetase null mice, but that does not appear to be the case in these null livers \[[@r72]; [@r113]\]. Failure to induce peroxisome proliferation in liver by dietary lipid overload also indicates that fatty acids per se are not effective PPARα ligands \[[@r54]\].

Experiments with liver-specific inactivation of fatty-acid synthase (FAS) suggest that products of FAS serve as endogenous activators of PPARα in adult liver \[[@r18]\]. FAS-deficient mice reveal a phenotype resembling PPARα deficiency \[[@r18]\]. Recently, it has been demonstrated that FAS generates 1-palmityl-2-oleolyl-*sn*-glycerol-3-phosphocholine (16:0/18:1-GPC), which appears to be a physiologically relevant PPARα ligand \[[@r17]\].

Leukotriene B4 (LTB4) is another well known putative PPARα ligand, which connects the receptor to inflammation and immune responses. 19- and 20-hydroxyeicosatetraenoic acid (19- and 20-HETE) are the major products of cytochrome P450 catalyzed conversion of arachidonic acid and play roles in the cardiovascular system, kidney function, cellular proliferation and inflammation. HETEs bind to and activate PPARα in HepG2 cells transfected with human PPARα, but do not show any transactivation activity when the cells are transfected with the unrelated nuclear receptor TRβ \[[@r135]\]. Oleylethanolamide (OEA), a naturally-occurring lipid has been identified as a high affinity PPARα ligand regulating PPARα activity and lipid metabolism. Finding a way of regulating PPARα activity through modulating endogenous ligand, and therefore achieving control of energy metabolism and body weight, may have the potential to generate new therapies.

A high degree of interest presently exists in discovering new partial agonists of PPARα and of other PPAR isoforms that are selective for beneficial effects of PPAR activation and avoid problems with dose-related toxicity and other negative side effects of PPAR activation \[[@r21]\]. Direct glucose binding with the receptor has also been shown to occur and may play an important regulatory role in PPARα activity, particularly in the setting of diabetes \[[@r74]\].

PPARα agonists, including fibrates such as fenofibrate, gemfibrozil and less commonly clofibrate, have been in use for several decades as therapeutic agents to decrease plasma levels of triglycerides and VLDL by enhancing lipid uptake and catabolism and to increase plasma levels of HDL-C \[[@r7]; [@r110]; [@r121]\]. The fibrate class of PPARα ligands increase the production in the liver of the apolipoproteins A-I and A-II, which are major components of HDL-C \[[@r7]\]. The search for agents that display potent and selective binding to the PPARα isotype that support robust recruitment of transcription coactivators is expected to result in the identification of new classes of ligands \[[@r94]\]. These novel ligands, including LY518674, a novel PPARα ligand recently reported by Nissen *et al.*, have the traditional benefits of reducing serum triglycerides and increasing serum HDL-C, but may confer additional benefits such as reduction of serum LDL-C, especially when paired with other treatments. Novel therapeutics such as this may hold the key to better treatments for lipid disorders such as atherogenic dyslipidemia, which lead to other metabolic and cardiac problems \[[@r138]\]. Other current therapeutic benefits of potential PPARα agonists are under investigation for use in the prevention of atherosclerosis, cardiomyopathies, ischemia-reperfusion injuries, prevention of angiogenesis, anti-proliferation of tumorigenic cells and others \[[@r15]; [@r38]; [@r237]; [@r122]; [@r142]; [@r144]; [@r155]; [@r196]; [@r210]\].

Other PPARα ligands with environmental impact, in particular phthalate ester plasticizers widely used in the manufacture of polyvinyl chloride plastics, and industrial solvents such as trichloroethylene have been in use for over 50 years. These are known contaminants of ground water and estuaries, but the impact on human health is unclear. More recently, certain herbicides have been shown to function as PPARα ligands, implying that these agents also constitute a major category of environmental contaminants that can activate this receptor, and thus raising issues about long-term or lifelong exposure.

PPARα heterodimerization with RXR, binding to DNA elements and PPARα-regulated genes
====================================================================================

PPARα, like many non-steroid members of the NR family, functions as an obligate heterodimer with another nuclear receptor, retinoid X receptor (RXR; NR2B) \[[@r98]\]. The PPARα/RXR heterodimers can form independent of the PPARα ligand and these unliganded heterodimers recruit corepressor protein complex and inhibit target gene transcription \[[@r44]\]. Upon ligand binding, the corepressor complex is released from the PPARα/RXR heterodimer, and the coactivator complexes will be recruited to the promoter region of target genes to initiate transcription \[[@r46]\]. The PPARα/RXR heterodimers bind to a specific DNA sequence element called a peroxisome proliferator response element (PPRE), which was initially characterized using the PPAR responsive promoter of the rat Acox1 gene \[[@r20]; [@r98]; [@r140]; [@r203]; [@r204]\]. This PPRE element is located in the promoter region of target genes \[[@r203]; [@r204]; [@r223]\]. The PPRE is of the direct repeat 1 (DR1) category, which is composed of two copies of the consensus hexamer sequence AGG(A/T)CA separated by a single base pair ([Figure 2](#fig2){ref-type="fig"}). Neither PPARα homodimers nor monomers bind to the PPRE. PPARα target genes usually contain one or more PPRE in the promoter and preferentially bind PPARα/RXR heterodimers \[[@r32]; [@r203]\]. Occasionally, PPRE may be in the proximal transcribed regions of certain target genes \[[@r43]\]. The PPRE element contains an additional AACT motif positioned 5' to the DR-1 \[[@r91]\]. This upstream extended hexamer of the DR1 interacts with PPARs, whereas the downstream hexamer is known to interact with RXR of the PPAR/RXR heterodimer \[[@r41]; [@r93]\]. Of the three PPARs, PPARγ binds more strongly than do PPARα and PPARβ/δ, implying that conservation of the 5'-flanking extension is more important for the binding of PPARα and PPARβ/δ \[[@r91]\]. The nature of this upstream extension may confer isotype specificity \[[@r78]\].

The presence of PPRE upstream of the fatty acyl-CoA oxidase 1 (ACOX1) gene \[[@r203]\], and peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (L-PBE) gene \[[@r223]\] were the first described. Interestingly, these were the first two genes identified to be transcriptionally activated by PPs \[[@r171]; [@r174]; [@r203]; [@r223]\]. Over the years, many other genes that possess PPREs have been characterized as PPARα target genes ([Supplementary File 1](#supplementary-material1){ref-type="supplementary-material"} and [Supplementary File 2](#supplementary-material2){ref-type="supplementary-material"}). cDNA microarray profiling and comparative proteomic data have revealed several known PPARα target genes and some new genes that are upregulated in liver by the PPARα ligand, Wy-14,643 \[[@r27]; [@r31]; [@r94]; [@r137]\]. These fall into several functional categories including lipid metabolism, xenobiotic metabolism, inflammation and others.

RXR, the heterodimerization partner of PPARs, is also a partner of many other NRs \[[@r14]; [@r92]; [@r118]\]. This promiscuous centrality of RXR in NR functioning, raises the possibility of competition between NRs for this common binding partner \[[@r92]\]. Reciprocal negative interaction between the PPARα and thyroid hormone receptor signaling pathways is indirect, in that it is mostly due to sequestration of RXR, the common heterodimeric partner \[[@r32]; [@r92]\]. A similar competition can also occur among PPAR isotypes with RXR in different cell types, but the *in vivo* effects of this competition and limiting amounts of RXR protein remain unclear \[[@r90]\].

PPARα knockout phenotype
========================

PPARα knockout mice were generated by the Gonzalez group \[[@r108]\]. These mice have demonstrated unequivocally that PPARα is indeed the bona fide receptor responsible for mediating the pleiotropic responses induced by synthetic peroxisome proliferators \[[@r108]\]. In this knockout mouse model, the ligand binding domain was disrupted by homologous recombination. Mice homozygous for the mutation did not express PPARα protein and yet are viable and fertile, with no detectable gross phenotypic defects \[[@r108]\]. PPARα null mice display normal basal levels of the inducible peroxisomal β-oxidation enzymes in liver, but generally lower levels of mitochondrial fatty acid metabolizing enzymes \[[@r3]\]. PPARα knockout mice do not reveal PP-induced pleiotropic responses when challenged with the classical peroxisome proliferators, clofibrate and Wy-14,643 \[[@r108]\]. Subsequently, it was shown that PPARα knockout mice fail to develop liver tumors when chronically exposed to these PPARα ligands, indicating that PP-induced hepatocarcinogenesis is receptor mediated, as previously proposed \[[@r64]; [@r70]; [@r146]; [@r156]\]. In essence, these observations clearly established that PPARα is the central player in mediating the pleiotropic responses of peroxisome proliferators \[[@r108]\]. Numerous studies with PPARα null mice during the past 15 years have demonstrated the critical roles played by this receptor in energy metabolism, hepatic steatosis, inflammation, cardiac pathophysiology, cell cycle alterations and hepatocarcinogenesis \[[@r110]\].

PPARα repressors and coactivators
=================================

Transcriptional activation of genes is a complex process, which involves the participation of many transcription coregulators \[[@r63]\]. PPARs, like other nuclear receptors, interact with coactivators such as SRC-1 (steroid receptor coactivator-1) \[[@r139]; [@r225]\], or corepressors such as N-CoR (nuclear corepressor) \[[@r26]; [@r46]\], and SMRT (silencing mediator for retinoid and thyroid hormone receptors) \[[@r26]; [@r46]; [@r76]\]. PPARα-interacting coactivators and corepressors augment or repress, respectively, the PPARα transactivation activity \[[@r55]; [@r220]; [@r230]\]. Since the cloning of SRC-1 \[[@r139]\] 15 years ago, over 300 coactivators/coregulators have been identified, with new members still being added to this expanding spectrum \[[@r115]\]. PPARα is known to interact with some of these coregulators ([Table 1](#table-fn1){ref-type="table"}). These include CBP/p300, three members of the SRC/p160 family, PBP/MED1 (PPAR-binding protein/TRAP220/DRIP205/mediator subunit 1), PRIP/NCoA6 (ASC2/RAP250/TRBP/NRC) \[[@r224]\], PRIC285, PRIC295, PRIC320, PGC-1α, and PGC-1β, as well as coactivator-associated proteins PIMT (NCoA6IP) and CARM-1 ([Table 1](#table-fn1){ref-type="table"}). The PPARα-interacting coregulator (PRIC) complex isolated from rat liver nuclear extracts reveals the presence of many of these coregulators, presumably forming one mega complex \[[@r200]\]. This diversity raises several issues about the evolutionary importance of the versatility and complexity of coregulatory molecules, their relative abundance in various cell types, and their affinity for a given nuclear receptor in orchestrating transcription in gene-, cell-, and developmental stage-specific transcription.

In the absence of a specific ligand, PPARα interacts with corepressors NCoR and SMRT, but the importance of this interaction for PPARα action is not well understood \[[@r55]\]. Homozygous deletion of NCoR or SMRT in mice is embryonic lethal, indicating that they cannot fully compensate for each other during development \[[@r62]; [@r83]; [@r84]\]. Furthermore, another corepressor, the Receptor Interacting Protein 140 (RIP140), which can interact with PPARα, is known to repress the activity of NRs by competing with coactivators and by recruiting downstream effectors such as histone deacetylases (HDACs) \[[@r213]\]. Interestingly, the phenotype of RIP140 knockout mice suggests a role for this corepressor in PPARα signaling, as these mice exhibit resistance to high-fat diet-induced obesity resulting from upregulation of genes involved in energy dissipation \[[@r111]\].

The binding of ligand to a nuclear receptor influences first, the release of corepressors and beginning recruitment of coactivator complexes, such as members of the SRC-1/p160 family, which exhibit histone acetyltransferase activity required to facilitate chromatin remodeling. Subsequent docking of other coregulators, either singly, or as preassembled multisubunit protein complexes, including mediator complex (MED), facilitates interaction of ligand-activated receptor with RNA polymerase and the general basal transcription machinery to enhance the transcription of a specific set of genes \[[@r45]; [@r63]; [@r191]\]. As indicated above, coactivators contain an LXXLL motif that forms two turns of α-helix and binds to a hydrophobic cleft on the surface of the nuclear receptor \[[@r207]\]. Data on the identification and characterization of coactivators have been derived mostly from *in vitro* observations, but there is a paucity of information about the *in vivo* cell- and gene-specific functional roles of individual coactivators \[[@r220]\].

Coactivator gene-knockout mice: PPARα signaling requires PBP/MED1
-----------------------------------------------------------------

Gene knockout mouse models have established that some of the coactivators are essential for embryonic growth and survival, while others are not critical for mouse embryogenesis \[[@r173]; [@r220]\]. For example, disruption of the PBP/MED1 gene results in embryonic lethality in the mouse around gestational day 11.5 \[[@r37]; [@r82]; [@r107]; [@r228]\]. Likewise, germ-line deletion of the PRIP/ASC2/NRC/RAP250/NCoA6 gene \[[@r2]; [@r152]\], and the PRIP-interacting protein PIMT/TGS1 (NCoA6IP) gene in the mouse also result in embryonic lethality \[[@r89]; [@r128]\]. In contrast, null mutation of coactivators SRC-1 \[[@r154]\], SRC-2 \[[@r30]\], and SRC-3, PGC-1, PRIC285 \[[@r206]\], and CARM1 result in a viable phenotype with or without overt functional changes.

Studies on the role of germ-line deletion of coactivators SRC-1, SRC-2, and SRC-3 in the mouse revealed that none of these are essential for PPARα ligand-induced pleiotropic responses in liver (\[[@r154]\] and Jia, Y., Xu, J., and Reddy, J.K., unpublished observations). These p160 family members are among the coactivators considered important for nuclear receptor function, but the *in vivo* results indicate their redundancy at least for PPARα function in liver \[[@r154]\]. It is likely that other coactivators with histone acetyltransferase activity may be adequate to facilitate chromatin remodeling in the absence of SRC-1 and other members of the p160 family \[[@r154]\]. Further studies are needed to ascertain the effects of loss of two or more members of this p160 family in PPARα function. Combined loss of p/CIP/SRC-3 and SRC-1 function has been shown to lead to a specific block in brown fat development, in part due to a failure of induction of PPARγ target genes \[[@r212]\]. Loss of both p/CIP/SRC-3 and SRC-1 also leads to increased food intake on both regular chow and a high-fat diet, indicating excess energy burning \[[@r212]\]. Whether loss of these two coactivators results in strongly increased energy expenditure by regulating PPARα- \[[@r174]; [@r175]\] and PPARβ/δ-dependent transcriptional activities \[[@r211]\] remains to be investigated.

To study the cell- and gene-specific functions of coactivator genes such as PBP/MED1 and PRIP/NCoA6, which when germ-line disrupted, lead to embryonic lethality in the mouse, it becomes necessary to generate conditional null mice using the Cre-loxP strategy \[[@r86]; [@r85]; [@r88]; [@r123]; [@r182]\]. Conditional deletion of PBP/MED1 gene in liver results in the abrogation of PPARα ligand-induced pleiotropic effects, indicating that PBP/MED1 is essential for PPARα signaling \[[@r86]; [@r123]\]. When fed a diet containing the PPARα ligands, Wy-14,643 or ciprofibrate, PBP/MED1 liver null mice revealed no peroxisome proliferation in PBP/MED1-deficient hepatocytes \[[@r85]\]. The presence of an occasional PBP/MED1-positive hepatocyte in these livers that escaped Cre-excision provided a characteristic visual contrast, in that such cells displayed the expected response to PPARα ligands, whereas the response of PBP/MED1-deficient hepatocytes was similar to that observed in cells that lacked PPARα \[[@r85]\]. PPARα ligand-induced liver cell proliferation was abolished in PBP/MED1 null hepatocytes and in these livers, residual PBP/MED1-expressing cells displayed a proliferative advantage \[[@r85]; [@r123]\]. Furthermore, PBP/MED1 is essential for partial hepatectomy-related liver regeneration and PPARα ligand Wy-14,643-induced receptor-mediated hepatocarcinogenesis \[[@r123]\]. PBP/MED1-deficient hepatocytes also fail to give rise to liver tumors following the administration of the genotoxic carcinogen diethylnitrosamine \[[@r124]\].

Deletion of the PBP/MED1 gene in liver also abolished the responses induced by constitutive androstane receptor (CAR) activators, phenobarbital or 1, 4-bis\[2-(3,5-dichloropyridyloxy)\]benzene (TCPOBOP) and of acetaminophen-induced hepatotoxicity \[[@r86]; [@r88]\]. In contrast, liver conditional knockout of the PRIP/NCoA6 gene had no effect on PPARα and CAR signaling in liver \[[@r182]\]. Mice with floxed PBP/MED1 \[[@r86]; [@r88]; [@r123]\], PRIP/NCoA6 \[[@r2]; [@r152]\], PIMT/TGS1/NCoA6IP \[[@r89]\], PRIC285 \[[@r206]\]; and PRIC320 (Viswakarma, N. and Reddy, J.K., unpublished observation) alleles should serve as valuable tools for conditional gene disruption in cells of interest to further evaluate the functional roles of PPARα.

PPARα functions
===============

PPARα and energy burning
------------------------

Obesity, resulting from increased consumption of energy-rich foods high in saturated fats and sugars, and reduced physical activity, has reached epidemic proportions globally, with more than 1 billion adults overweight \[[@r214]\]. When consumption of energy far exceeds the combustion of calories, there is increased deposition of long-chain fatty acids, principally in the form of triglycerides in adipose and other tissues leading to obesity \[[@r51]\]. All three members of the PPAR subfamily of nuclear receptors have been shown to participate in energy metabolism in that PPARα and PPARβ/δ function mostly as catabolic regulators of energy expenditure, while PPARγ regulates anabolic metabolism in that it plays a role in energy storage \[[@r22]; [@r23]; [@r34]; [@r51]; [@r102]; [@r202]\].

The liver is a central player in the whole body energy homeostasis by its ability to orchestrate fatty acid and glucose metabolism. Hepatic lipid metabolism principally involves three aspects: *lipogenesis*, *oxidation of fatty acids* and *secretion of lipids*. Lipogenesis consists of de novo fatty acid synthesis and subsequent conversion of these fatty acids into triglycerides. In the liver, lipogenesis is regulated by transcription factors, sterol regulatory element-binding protein (SREBP-1c), carbohydrate response-element binding protein (ChREBP) and PPARγ \[[@r13]; [@r73]; [@r211]; [@r219]\]. SREBP-1c regulates the expression of constellations of glycolytic and lipogenic genes, including stearoyl CoA desaturase (Scd-1) and fatty acid synthase (Fas) \[[@r71]; [@r73]; [@r175]\]. Emerging evidence suggests that PPARα also influences lipogenesis by increasing the transcription of *Scd-1* and other lipogenic genes by regulating the primary transcription factors SREBP-1c and liver X receptor α (LXRα) \[[@r71]\]. It is suggested that PPARα participates in the generation of an endogenous LXRα ligand, since a synthetic, non-steroidal ligand of LXRα has been found effective in the induction of lipogenic genes in mice deficient in PPARα \[[@r71]\]. However, the role of PPARα in lipogenesis, albeit modest, is intriguing, as it appears paradoxical to the well-known role of this transcription factor in the regulation of fatty acid oxidation \[[@r174]\]. The involvement of PPARα in lipogenesis may suggest a fail-safe compensatory mechanism for the removal of important fatty acids, for example, during starvation \[[@r71]\].

Liver plays an important role in *fatty acid oxidation* and this catabolic energy burning is regulated by PPARα \[[@r174]; [@r175]\]. Oxidation of fatty acids occurs in three subcellular organelles, with the bulk of β-oxidation confined to mitochondria and peroxisomes, while CYP4A-catalyzed ω-oxidation takes place in the endoplasmic reticulum \[[@r158]; [@r174]\]. Some of the key enzymes involved in these three fatty acid oxidation systems possess PPRE elements and are regulated by PPARα, though PPARβ/δ has also been shown to regulate some of these genes \[[@r41]; [@r170]; [@r174]; [@r180]; [@r204]; [@r205]\]. Fatty acids are converted into acyl-CoAs prior to oxidation.

Mitochondrial β-oxidation is primarily involved in the oxidation of the major portion of the short-(\<C~8~), medium-(C~8~-C~12~) and long-(C~12~-C~20~) chain fatty acids, and in the process, constitutes the primary source of energy derived from fatty acids \[[@r174]\]. The PPARα-regulated enzymes, long chain acyl-CoA synthetases and carnitine palmitoyl transferase-1, are essential, respectively, for generating fatty acyl-CoA, and facilitating the entry of fatty acyl carnitine into mitochondria \[[@r33]\]. The first step in mitochondrial β-oxidation is comprised of α-β-dehydrogenation of the fatty acyl-CoA ester by a family of four chain length specific straight chain acyl-CoA dehydrogenases \[[@r68]; [@r174]\]. These include very-long chain, medium chain and short chain enzymes. A heterotrimeric protein, exhibiting 2-enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase, and 3-keto acyl-CoA thiolase activities, participates in the second, third and fourth steps in the mitochondrial β-oxidation pathway \[[@r68]; [@r175]\]. Mitochondrial β-oxidation results in the progressive shortening of fatty acids into acetyl-CoA subunits. These either condense into ketone bodies to serve as oxidizable energy substrates for extrahepatic tissues, especially during starvation, or enter into the tricarboxylic acid cycle for further oxidation to water and carbon dioxide \[[@r174]; [@r175]\].

Peroxisomal β-oxidation is streamlined toward the metabolism, almost exclusively, of very long straight-chain fatty acids (\>C~20~), 2-methyl branched fatty acids (e.g., pristanic acid that is generated by α-oxidation of the 3-methyl-branched fatty acid phytanic acid), prostanoids, dicarboxylic acids, and the C~27~ bile acid intermediates di- and trihydroxycoprostanoic acids \[[@r57]; [@r87]\]. Substrates for peroxisomal β-oxidation are less abundant and relatively more toxic, and they are not processed by the mitochondrial β-oxidation system \[[@r175]\]. However, peroxisomal β-oxidation is required to shorten the chain length of very long chain fatty acids and chain-shortened acyl-CoAs are shunted to mitochondria for the completion of β-oxidation \[[@r174]\]. The coordinate inducibility of peroxisomal β-oxidation system enzymes by peroxisome proliferators in now well established \[[@r174]; [@r165]\] and this induction is regulated by PPARα \[[@r81]; [@r99]; [@r108]\].

Peroxisomal β-oxidation consists of four metabolic steps and each metabolic conversion can be performed by at least two different enzymes \[[@r68]; [@r174]\]. Some of these enzymes are inducible by peroxisome proliferators, while others seem refractive to induction by these PPARα ligands \[[@r174]\]. Straight-chain fatty acyl-CoAs serve as substrates for the classical inducible pathway, whereas the second non-inducible β-oxidation enzyme system acts on 2-methyl-branched fatty acyl-CoAs \[[@r68]\]. In the inducible PPARα-regulated peroxisomal β-oxidation pathway, fatty acyl-CoA oxidase 1 (ACOX1) is responsible for the initial oxidation of very-long-chain fatty acyl-CoAs to their corresponding trans-2-enoyl-CoAs. On the other hand, the non-inducible fatty acyl-CoA oxidase 2 (ACOX2) serves as the first step in the metabolism of branched-chain fatty acyl-CoAs. The second and third reactions in the inducible β-oxidation system, hydration and dehydrogenation of enoyl-CoA esters to 3-ketoacyl-CoA are catalyzed by a single bifunctional enzyme enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase (L-PBE/MFP1). Ketoacyl-CoAs generated by L-PBE/MFP1 are then converted by 3-ketoacyl-CoA thiolase (PTL) to acetyl-CoA and to an acyl-CoA that is two carbon atoms shorter than the original molecule. The shortened acyl-CoA reenters the β-oxidation cycle, and this process repeats for about 5 cycles, resulting in the removal of ten carbon atoms. The appropriately chain-shortened acyl-CoAs are then transported to mitochondria for the completion of β-oxidation \[[@r68]\]. All three genes of this classical inducible peroxisomal β-oxidation system (ACOX1, L-PBE/MFP1, and PTL) are tightly regulated by PPARα. Of interest is that L-PBE/MFP1 protein is induced abundantly in the livers of rats and mice treated with peroxisome proliferators and accounts in part for the increase in peroxisome population \[[@r87]; [@r160]\]. Although, L-PBE/MFP1 is highly inducible by both synthetic and natural PPARα ligands in liver, the functions carried out by this enzyme can be also performed highly effectively by the D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase (D-bi/multifunctional enzyme 2; D-PBE/MFP2) \[[@r68]; [@r87]\]. 3-ketoacyl-CoAs generated by D-PBE/MFP2 of the non-inducible pathway are cleaved by the third enzyme of this system, sterol carrier protein X, which possesses thiolase activity \[[@r68]\].

In addition to mitochondrial and peroxisomal β-oxidative processing, fatty acids are also oxidized by microsomal ω-oxidation carried out by CYP4A enzymes that are regulated by PPARα \[[@r174]\]. The first step of ω-hydroxylation of saturated and unsaturated fatty acids occurs in the endoplasmic reticulum and the resulting ω-hydroxy fatty acid is then dehydrogenated to yield highly toxic dicarboxylic acids in the cytosol. Dicarboxylic acids are converted to dicarboxylyl-CoAs and enter peroxisomes for further metabolism by the classical inducible β-oxidative enzymes \[[@r56]; [@r175]\]. Dicarboxylic acids are unique in that they serve as substrates for the peroxisomal β-oxidation system and also as ligands for PPARα \[[@r68]\]. It would appear that dicarboxylic fatty acids streamline their own metabolism by inducing PPARα activation and thus regulating all three fatty acid oxidation enzyme pathways \[[@r174]\].

In summary, the PPARα regulates all three fatty acid oxidation systems. Gene knockout mouse models have provided evidence to indicate that substrates for peroxisomal β-oxidation function as PPARα ligands to enhance energy burning. In this regard, hyperactivation of PPARα by pharmacological intervention might prove to be useful as an adjuvant to exercise in combating obesity in individuals who are refractory to modulating energy consumption. PPARα ligands do not appear to cause weight loss independent of PPARα activation.

PPARα and hepatic steatosis
---------------------------

Fatty liver disease is the most common liver disease, as it encompasses a morphological spectrum of hepatic steatosis and steatohepatitis that progresses to cirrhosis and hepatocellular carcinoma \[[@r159]; [@r175]; [@r221]\]. Fatty liver disease occurs worldwide in those with excess alcohol consumption (*alcoholic fatty liver disease*), and those who are obese with or without added insulin resistance (*non-alcoholic fatty liver disease*) \[[@r39]; [@r51]; [@r66]; [@r175]; [@r195]\]. Several metabolic and genetic diseases that influence fatty acid metabolism also develop fatty liver disease \[[@r13]; [@r175]\]. Fatty liver disease is the culmination of increased energy uptake, increased hepatic lipogenesis, decreased energy combustion and decreased hepatic secretion of liver triglycerides. PPARα gene knockout mice have provided valuable clues regarding the role of this transcription factor in energy metabolism by liver.

By virtue of its unique ability to orchestrate fatty acid oxidation, PPARα appears to play a significant role in the pathogenesis of hepatic steatosis. First, as indicated above, PPARα influences the expression of hepatic lipogenic genes by regulating the primary transcription factors SREBP-1c and liver X receptor α (LXRα) \[[@r13]; [@r71]\]. Second, in conditions for increased demand for fatty acid oxidation, such as starvation, PPARα is essential for the upregulation of some of the enzymes necessary for this process, though PPARβ/δ has recently been shown to be important in regulating some of these genes independently of PPARα \[[@r180]\]. Under fasted conditions, PPARα senses the lipid influx into the liver and upregulates all three fatty acid oxidation systems to burn the energy and minimize hepatic steatosis \[[@r69]; [@r96]; [@r112]\]. PPARα null mice are unable to efficiently induce the expression of genes involved in the oxidization of fatty acids released from adipose tissue. Accordingly, PPARα-deficient mice exhibit hepatic steatosis, hyperlipidemia and hypothermia \[[@r69]; [@r96]; [@r112]\]. PPARα null mice also develop severe steatohepatitis compared to wild-type mice when maintained on a diet deficient in methionine and choline \[[@r80]\]. Furthermore, upon treatment with PPARα ligands there is an attenuation of methionine-choline deficient diet-induced steatohepatitis \[[@r158]\].

PPARα null mice fed ethanol develop marked hepatomegaly, steatohepatitis, and liver cell death and proliferation, implying a role for decreased fatty acid oxidation in mice deficient in this transcription factor \[[@r133]\]. Furthermore, ethanol is known to inhibit fatty acid oxidation and this is attributed to ethanol inhibition of PPARα transcription \[[@r195]\]. Hypo-activity of PPARα might play a role in the severity of alcohol liver disease in the human. On the other hand, it has been shown that PPARα activation is essential for hepatitis C virus (HCV) core protein-induced hepatic steatosis and hepatocellular carcinoma in mice \[[@r201]\].

PPARα and hypolipidemic effects
-------------------------------

PPARα ligands reduce VLDL production and enhance the catabolism of TG-rich particles, which indirectly decreases small dense LDL (sdLDL) particles, enhancing the formation of HDL particles and hepatic elimination of excess cholesterol \[[@r110]\]. PPARα upregulates lipoprotein lipase transcription in liver and muscle and this leads to increased TG hydrolysis.

The activity of ApoC-III, which is an inhibitor of both LPL activity and remnant clearance, is lowered by PPARα agonists \[[@r146]\]. PPARα agonists induce ABCA1 and SR-BI expression in macrophages. HDL apolipoprotein genes apoA-I and apoA-II are activated by PPARα by direct transcriptional control \[[@r41]; [@r110]; [@r146]\]. Thus, PPARα activation by fibrates and other compounds, elicits a global normolipidemic response, by reducing TG-rich particle production, increasing their lipolysis, and promoting HDL metabolism \[[@r110]\].

PPARα and inflammation
----------------------

Evidence indicates that PPARα plays a beneficial role in reducing inflammation. Activation of this receptor appears to influence both acute and chronic inflammatory disorders involving neutrophils and macrophages. Leukotriene B~4~ (LTB4), a powerful chemotactic inflammatory eicosanoid, is an endogenous PPARα ligand ([Figure 2](#fig2){ref-type="fig"}). Like other PPARα ligands, it induces transcription of genes of the β- and ω-oxidation pathways that neutralize and degrade LTB4 itself to regulate the inflammatory response \[[@r42]; [@r58]\]. Absence of PPARα prolongs the LTB4-induced inflammatory response \[[@r42]\]. Agents containing LTB4 or its precursor arachidonic acid, when applied to the ears of PPARα knockout and wild-type mice, showed that the inflammatory response was significantly prolonged in PPARα null mice, compared to the wild-type controls \[[@r42]\]. These data established that PPARα regulates the duration of the inflammatory response, possibly through limiting cytokine expression and by inducing genes that metabolize LTB4 \[[@r42]\]. Based on these observations, it is logical to surmise that PPARα ligands exert potential anti-inflammatory effects in modulating various inflammatory processes such as atherogenesis and hepatitis \[[@r42]; [@r176]; [@r196]; [@r222]\].

Macrophages are mediators of inflammation in the vasculature and participate in the development of atherosclerotic plaques \[[@r186]\]. In the pathogenesis of atherosclerosis, PPARα activation could result initially in reduced leukocyte adhesion to activated endothelial cells of the arterial lumen, and subsequently in inhibiting the formation of macrophage foam cells by regulating expression of genes involved in reverse cholesterol transport and reactive oxygen species output \[[@r29]; [@r222]\]. Accordingly, activation of PPARα may be beneficial in curtailing the inflammatory response and, in particular, the formation and progression of atherosclerotic plaques by minimizing lipoprotein oxidative modifications.

PPARα ligands significantly reduce the levels of pro-inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) by inhibiting the translocation of the p65 subunit of nuclear factor κ-B (NF-κB) and decreasing phosphorylation of the c-jun subunit of AP-1 \[[@r155]\]. Loss of PPARα-mediated gene transcription in PPARα null macrophages resulted in enhanced MAPK phosphorylation, leading to increased NF-κB \[[@r38]\]. Several other studies have also demonstrated a similar, important role for PPARα in modulating inflammation in vascular endothelial cells, cartilage and bone tissue, kidney, adipose tissue, and glial cells in the central nervous system (CNS) \[[@r97]; [@r101]; [@r130]; [@r149]; [@r197]\]. These studies may point toward potential new roles for PPARα and PPARα target genes as therapeutic targets in disorders involving inflammation such as atherosclerosis, joint disease, and autoimmune disorders such as multiple sclerosis \[[@r4]; [@r48]\].

PPARα and liver cancer
----------------------

The development of HCC in mice fed a diet containing nafenopin, a potent peroxisome proliferator, was first reported in 1976 \[[@r162]\]. Subsequently, several hypolipidemic compounds and plasticizers such as DEHP and DEHA have also been shown to induce liver tumors in rats and mice \[[@r100]; [@r156]; [@r169]\]. Rodents exposed to peroxisome proliferators develop hepatomegaly, largely due to the early hyperplastic and hypertrophic growth of hepatocytes \[[@r169]; [@r161]; [@r163]\]. With chronic exposure, hepatic adenomas and hepatocellular carcinomas develop in these rodents \[[@r157]; [@r169]; [@r162]\]. The latency period and the incidence of liver tumors appear to correlate well with the effectiveness of a given compound to induce peroxisome proliferation-associated pleiotropic responses \[[@r157]\]. Phenotypic features of peroxisome proliferator-induced liver tumors differ from those induced by classic genotoxic hepatocarcinogens \[[@r157]\]. Since peroxisome proliferators are neither DNA damaging nor mutagenic, it was proposed that these compounds constitute a novel class of nongenotoxic hepatocarcinogens and this concept laid the foundation for the receptor-mediated hepatocarcinogenesis \[[@r156]; [@r169]; [@r168]; [@r217]\].

Peroxisome proliferators do not directly cause genetic damage. It became increasingly evident that hepatocarcinogenicity is due to metabolic alterations resulting from sustained receptor activation that contribute to oxidative stress induced DNA damage in liver \[[@r147]; [@r156]; [@r168]; [@r179]; [@r217]\]. In normal liver, hydrogen peroxide is produced as a byproduct of many oxidative reactions \[[@r217]\]. Of these, the catabolism of very long chain fatty acids, resulting from massive induction of the peroxisomal fatty acid oxidation system by peroxisome proliferators, has received considerable attention in peroxisome proliferator-induced liver carcinogenesis \[[@r134]; [@r166]\]. Peroxisomal catalase degrades hydrogen peroxide in normal liver, but in livers with peroxisome proliferation catalase expression increases \~2- to 5-fold in contrast to disproportionately large increases in hydrogen peroxide producing acyl-CoA oxidase and microsomal ω-oxidation enzymes \[[@r31]; [@r134]; [@r217]\]. This imbalance between the expression of enzymes capable of producing- and degrading- hydrogen peroxide and other reactive oxygen species in hepatocytes contribute to oxidative stress, lipid peroxidation and oxidative DNA damage \[[@r156]\]. These changes influence lipofuscin accumulation, a product of the oxidation of unsaturated fatty acids, as well as hepatocellular proliferation \[[@r147]; [@r157]; [@r166]\]. DNA damage through oxidative stress and hepatocellular proliferation, together, are considered as possible mechanisms responsible for the development of hepatocellular carcinomas in rodents chronically exposed to peroxisome proliferators \[[@r147]; [@r156]; [@r160]; [@r169]\]. Consistent with this concept is a concordant marked induction in the liver of genes specific for the long-patch base excision DNA repair following exposure to PPARα ligand, Wy-14,643 \[[@r179]\]. Long-patch base excision DNA repair is a predominant pathway that removes oxidized DNA lesions \[[@r179]\]. It is evident that DNA-damaging oxidants are generated by enzymes induced after activation of PPARα, such as those involved in fatty acid oxidation \[[@r179]\]. Based on these observations, it is concluded that chronic exposure to synthetic peroxisome proliferators results in sustained activation of PPARα and transcriptional activation of PPARα responsive genes that affect intermediary metabolism in liver \[[@r170]; [@r174]\]. These metabolic changes, along with the anti-apoptotic effects of PPARα activation, contribute to oxidative DNA damage and increased hepatocellular proliferation leading to liver cancer development \[[@r25]; [@r147]; [@r170]\].

Levels of regulation of PPARα transcriptional activity
======================================================

Although it has been well-demonstrated that peroxisome proliferation and liver cancer develop in rodent models, it is not clear that chronic administration of PPARα ligands leads to tumorigenesis in humans. However, many factors may contribute to this variability seen in species- and cell-specific responses to PPARα ligands. The levels of regulation of PPARα-induced responses ([Figure 3](#fig3){ref-type="fig"}) include: the potency of specific exogenous and endogenous PPARα ligands to activate PPARα \[[@r54]; [@r162]\], differential expression of the PPARα and its heterodimerizing partner RXR \[[@r141]\], species differences in the promoter regions of PPARα target genes \[[@r170]\], differential expression of certain coactivator proteins necessary for PPARα-mediated transactivation and differing expression levels and activity of PPARα target genes \[[@r85]; [@r220]\].

PPARα ligands show an intrinsic difference in their capability to induce maximal PPARα activation and peroxisome proliferation. Male F344 rats require feeding of DEHP at a 2% (w/w) dietary level for 30 days in order to achieve a significant degree of hepatomegaly and peroxisome proliferation, while rats fed for the same period on a diet containing only 0.01% ciprofibrate show a significant increase in liver to body weight ratio \[[@r171]\]. Ciprofibrate is more effective at inducing the classical peroxisome proliferative response when compared to phthalate ester plasticizers such as DEHP. Furthermore, it should be noted that hepatic peroxisome proliferation is inducible in the livers of several species including cats, chickens, pigeons and the nonhuman primates such as rhesus and cynomologus monkeys by ciprofibrate at dose levels that exceed therapeutic levels \[[@r104]; [@r164]\]. It would appear that induction of peroxisome proliferation, in part, can be dose-dependent, but not a species-specific phenomenon.

Tissue levels of expression of the PPARα receptor may help explain the differences seen in response to treatment with PPARα agonists. In the mouse, liver, kidney and heart use fatty acid β-oxidation as a source of fuel. In these tissues, the basal levels of mitochondrial β-oxidation enzymes are similar. However, liver shows a much higher degree of induction of PPARα-regulated fatty acid oxidation enzymes than kidney or heart \[[@r34]\]. PPARα levels appear to be lower in human livers, as compared to rodent livers, and have been proposed to account for reduced response of human liver to peroxisome proliferation \[[@r141]\]. Since these estimates were from post mortem livers, data on freshly obtained liver biopsy samples will be required for reliable comparison \[[@r141]; [@r160]\]. Adenoviral overexpression of human PPARα in PPARα-null mouse liver restored peroxisome proliferator-induced pleiotropic responses in liver, including peroxisome proliferation, induction of PPARα target genes and liver cell proliferation \[[@r218]\].

The PPARα transactivational response is also regulated by the nature of the PPRE sequence present in the promoter region of responsive genes. PPARα may regulate gene activity in conjunction with other transcription factors such as CCAAT/enhancer-binding protein (C/EBP), sterol regulatory element binding protein 1 (SREBP1), TATA-binding protein (TBP) and members of the signal transducer and regulator of transcription (STAT) family \[[@r204]\]. The presence or absence of motifs which bind these other transcription factors in the promoter regions of PPARα target genes had a significant influence on the ability of PPARα to transactivate or transrepress expression of those genes. Species differences in the promoter regions of PPARα target genes may account for some of the differences observed in response to treatment with PPARα ligands.

As previously discussed, coactivator proteins are required for effective transactivation of target genes by PPARα. The protein, PBP/MED1, when disrupted in mouse liver, results in the abrogation of peroxisome proliferation and other pleiotropic effects of treatment with PPARα ligands \[[@r85]; [@r123]\]. The degree of expression of different coactivator proteins such as PBP/MED1, and the particular milieu of coactivators expressed in a particular tissue, organism, or species may therefore also contribute to the variable species response to treatment with PPARα ligands.

Recently, it has been shown that activation of PPARα represses the expression of the let-7C miRNA, which in turn releases the repression of c-myc expression \[[@r188]\]. Interestingly, mice expressing the human PPARα protein do not show this repression of the let-7C miRNA \[[@r216]\]. Accordingly, these mice also do not exhibit hepatocellular proliferation or development of tumors \[[@r64]; [@r127]; [@r188]\]. This induced expression of c-myc protein is proposed to be the mechanism contributing to PPARα ligand-induced hepatocellular proliferation \[[@r188]\]. Increased cell proliferative stimulus mediated by PPARα ligands in an intense oxidative stress inducing environment in livers with peroxisome proliferation, could act in concert and contribute to the development of liver tumors. Nonetheless, the level of human PPARα expression may be an issue for consideration in humanized PPARα mice, since adenoviral overexpression of human PPARα in PPARα-null mice showed robust liver cell proliferation in response to a synthetic PPARα ligand \[[@r218]\]. Accordingly, sustained activation of PPARα by synthetic ligands is hepatocarcinogenic, as observed in rodent models \[[@r170]\].

Additionally, PPARα activity is influenced by the ability of target genes, such as ACOX1 to efficiently metabolize and thus remove endogenous ligands in hepatocytes. In ACOX1 null mouse livers, PPARα activity is dramatically increased as a result of the accumulation of unmetabolized, endogenous ligands \[[@r34]; [@r54]; [@r217]\]. As a result, species differences in the expression of PPARα target genes may also contribute to species-specific responses to treatment with PPARα ligands. ACOX1 null mouse livers display the hallmarks of PPARα activation such as hepatocellular regeneration accompanied by profound generalized spontaneous peroxisome proliferation, and increased mRNA levels of genes that are regulated by PPARα, which ultimately lead to liver tumor development \[[@r54]\]. Although ACOX1, a major hydrogen peroxide generating enzyme in peroxisomes, is absent in these livers, there appear to be other sources that may contribute to oxidative stress in liver such as cytochrome P450 family proteins induced by activated PPARα \[[@r54]; [@r174]; [@r217]\]. These CYP4A proteins typically catalyze the addition of oxygen to a variety of substrate molecules and may produce reactive oxygen as a by-product \[[@r160]; [@r174]; [@r217]\]. Thus, it would be essential to consider that ACOX1 is not the only source of oxidative stress in PPARα-activated livers. Expression of long-patch base excision DNA repair genes was found to be upregulated significantly in livers of naïve ACOX1-null mice and was increased similarly to the effect of WY-14,643 \[[@r179]\]. These observations strongly support that sustained activation of PPARα in liver, either by synthetic or natural ligands, leads to endoplasmic reticulum and oxidative stress. Liver tumors that develop in ACOX1 null livers exhibit similar cDNA profiles as tumors resulting from long-term treatment with PPARα ligands, but not similar to tumors resulting from treatment with diethylnitrosamine, a genotoxic mutagen \[[@r54]; [@r126]\]. These observations further support the novel nature of PPARα ligand-induced hepatocarcinogenesis.

PPARα polymorphism
==================

Genetic variation and polymorphism of PPARα in the human have been under intensive study \[[@r16]\]. To date, at least 14 polymorphisms of PPARα have been reported ([Figure 1](#fig1){ref-type="fig"}) \[[@r132]\] and include P22R, D140Y \[[@r67]\], R127Q (rs1800204), R131Q \[[@r181]\], L162V (rs1800206), R178G \[[@r136]\], V227A (rs1800234), A268V (rs1042311), D304N (rs1800242), G395A (rs2229245), D409T (rs1800243), Q413L (rs9615759), D140N and G395E \[[@r132]\]. Some of these variations were reportedly associated with human lipid metabolic changes. For example, PPARα-V227A is a major polymorphism in the Japanese population \[[@r132]\]. Its activity may be greater than that of wild-type PPARα, but is decreased by increased alcohol consumption, suggesting that alcoholic liver injury may affect the activity of this receptor \[[@r132]\]. Among the 4,248 subjects from 3 ethnic groups (2,899 Chinese, 761 Malay and 588 Asian Indians) genotyped for polymorphisms at the *PPARA* locus, allele frequencies for the V227A mutation were 0.04 in Chinese, 0.006 in Malays and 0.003 in Asian Indians \[[@r19]\]. This polymorphism is associated with lower serum concentrations of total cholesterol and triglycerides in Chinese women. The V227A polymorphism is believed to modulate the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentration. These observations suggest that genetic variation of PPARα may determine the response to changes in dietary PUFA intake \[[@r19]\]. Furthermore, L162V polymorphism in the PPARα gene, first identified in the Caucasian population \[[@r181]; [@r208]\], was associated with increased levels of serum apolipoprotein B and LDL cholesterol. The L162V polymorphism in PPARα may determine the response to PPARα ligands \[[@r10]\]. The PPARα-L162V polymorphism alone or in interaction with dietary fat intake is associated with components of the metabolic syndrome and may contribute to variability in plasma lipoprotein and lipid response after modification of the dietary polyunsaturated to saturated fatty acids ratio \[[@r143]; [@r178]; [@r181]; [@r208]\].

Conclusions
===========

Studies with a structurally diverse group of chemicals designated as peroxisome proliferators laid the foundation for the discovery of a subfamily of nuclear receptors named peroxisome proliferator-activated receptor (PPAR) with three members: PPARα, PPARβ/δ and PPARγ. Of these, PPARα plays a critical role in fatty acid oxidation and is thus responsible for energy expenditure. Sustained activation of PPAR leads to the development of liver tumors in rats and mice, whereas PPARα deficiency leads to impaired response to fatty acid influx into liver and contributes to hepatic steatosis. Studies with gene knockout mouse models have yielded information on putative endogenous PPARα ligands that are either generated or degraded by certain enzymes during intermediary metabolism. Several nuclear receptor coactivators have been noted to interact with PPARα, but studies to-date indicate that the coactivator PBP/MED1 is essential for PPAR target gene activation, liver cell proliferation and liver tumorigenesis. As for future challenges, it remains to be determined the extent and nature of other endogenous PPAR agonists and other coactivators that influence PPARα function. Such information may provide clues for therapeutic intervention to enhance energy utilization, minimize the adverse effects of both alcoholic and nonalcoholic fatty liver disease and modulate liver cell proliferation.

ACOX1

:   peroxisomal fatty acyl-CoA oxidase 1

CBP

:   cAMP response element-binding protein-binding protein

CYP

:   cytochrome P450

D-PBE

:   D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase (D-bifunctional enzyme)

DRIP

:   vitamin D receptor-interacting protein(s)

FACS

:   fatty acyl-CoA synthetase

FAS

:   fatty acid synthase

L-PBE

:   enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase (L-bifunctional enzyme)

MED1

:   mediator subunit 1

PBP

:   PPAR-binding protein

PIMT

:   PRIP-interacting protein with methyltransferase activity

PPAR

:   peroxisome proliferator-activated receptor

PPRE

:   PPAR response element

PRIC

:   PPARα-interacting coregulator complex

PRIP

:   PPAR-interacting protein

PTL

:   peroxisomal thiolase

RXR

:   retinoid X receptor

SRC-1

:   steroid receptor coactivator-1

TRAP

:   thyroid hormone receptor-associated protein

Supplementary Material
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.
